Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;58(5):2740-6.
doi: 10.1128/AAC.02476-13. Epub 2014 Feb 24.

In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy

Affiliations

In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy

Kady Phe et al. Antimicrob Agents Chemother. 2014 May.

Abstract

Despite concerns of nephrotoxicity, polymyxin antibiotics often remain the only susceptible agents for multidrug-resistant (MDR) Gram-negative bacteria. Colistin has been more commonly used clinically due to a perceived safety benefit. We compared the nephrotoxicity of colistin to polymyxin B. The in vitro cytotoxicity of colistin was compared to polymyxin B in two mammalian renal cell lines. To validate the clinical relevance of the findings, we evaluated adult patients with normal renal function who received a minimum of 72 h of polymyxin therapy in a multicenter study. The primary outcome was the prevalence of nephrotoxicity, as defined by the RIFLE (risk, injury, failure, loss, end-stage kidney disease) criteria. Colistin exhibited an in vitro cytotoxicity profile similar to polymyxin B. A total of 225 patients (121 receiving colistimethate, 104 receiving polymyxin B) were evaluated. Independent risk factors for colistimethate-associated nephrotoxicity included age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.00 to 1.07; P = 0.03), duration of therapy (OR 1.08; 95% CI, 1.02 to 1.15; P = 0.02), and daily dose by ideal body weight (OR 1.40; 95% CI, 1.05 to 1.88; P = 0.02). In contrast, cystic fibrosis was found to be a protective factor in patients who received colistimethate (OR, 0.03; 95% CI, 0.001 to 0.79; P = 0.04). In a matched analysis based on the risk factors identified (n = 76), the prevalence of nephrotoxicity was higher with colistimethate than with polymyxin B (55.3% versus 21.1%; P = 0.004). Polymyxin B was not found to be more nephrotoxic than colistin and may be the preferred polymyxin for MDR infections. A prospective study comparing the two polymyxins directly is warranted.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Comparison of nephrotoxicity rates. *, P = 0.003.
FIG 2
FIG 2
Comparison between the matched cohorts of the onset of nephrotoxicity. Patients who fell into any category of the RIFLE definition for nephrotoxicity were included. Solid line, polymyxin B cohort; dashed line, colistin cohort (P = 0.003).

References

    1. Kwa AL, Low JG, Lee E, Kurup A, Chee HL, Tam VH. 2007. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn. Microbiol. Infect. Dis. 58:99–104. 10.1016/j.diagmicrobio.2006.11.014 - DOI - PubMed
    1. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. 2010. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob. Agents Chemother. 54:3717–3722. 10.1128/AAC.00207-10 - DOI - PMC - PubMed
    1. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser TG, van Duin D. 2011. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn. Microbiol. Infect. Dis. 69:357–362. 10.1016/j.diagmicrobio.2010.10.013 - DOI - PMC - PubMed
    1. Kwa A, Kasiakou SK, Tam VH, Falagas ME. 2007. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev. Anti. Infect. Ther. 5:811–821. 10.1586/14787210.5.5.811 - DOI - PubMed
    1. Nord NM, Hoeprich PD. 1964. Polymyxin B and colistin. A critical comparison. N. Engl. J. Med. 270:1030–1035. 10.1056/NEJM196405142702002 - DOI - PubMed

Publication types

LinkOut - more resources